Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
|Metastatic Breast Cancer||Drug: Bevacizumab, docetaxel, cisplatin||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer|
- Response Rate [ Time Frame: every 3 months ]
- Time to Progression(TTP), Progression free survival, overall survival, safety, Quality of Life [ Time Frame: every 3 months ]
|Study Start Date:||January 2005|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
Experimental: metastatic breast cancer
Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
Drug: Bevacizumab, docetaxel, cisplatin
Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.
docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.
cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01025349
|Taipei Medical University Hospital|
|Taipei, Taiwan, 110|
|Principal Investigator:||Cheng-Jeng Tai, M.D.||Section of Hematology-Oncology, Department of Medicine, Taipei Medical University Hospital|